Edwards Champions American Heart Association Initiative to Reduce Deaths, Improve Care for Patients With Heart Valve Disease
NEW ORLEANS–(BUSINESS WIRE)–Edwards Lifesciences (NYSE: EW) today announced its founding sponsorship of the American Heart Association’s Heart Valve... Read more.
Best’s Market Segment Report: AM Best Maintains Stable Outlook on New Zealand’s Life Insurance Segment
SINGAPORE–(BUSINESS WIRE)–#insurance—AM Best is maintaining its stable outlook on the New Zealand life insurance segment, based in part on improving... Read more.
Stepful Keeps Healthcare Training Free for Military Families Amid Government Shutdown
NEW YORK–(BUSINESS WIRE)–As the government shutdown continues to disrupt funding for education and workforce programs, Stepful, recently named the #1... Read more.
Anumana Advances AI-Driven Cardiovascular Science with Late-Breaking Heart Failure Study and Multiple Abstracts at AHA 2025
Simultaneous publication in Journal of the American College of Cardiology demonstrates impact of ECG-AI on heart failure risk assessment CAMBRIDGE, Mass.–(BUSINESS... Read more.
Teledyne FLIR Defense Names Riyadh-Based Managing Director for Middle East and North Africa
Tarik Solomon to lead regional growth strategy, strengthen partnerships, and help Teledyne position the Kingdom as a hub for next-generation defense and dual-use... Read more.
Workers at Aimbridge-operated hotels in Los Angeles and Philadelphia strike during event-filled weekend, UNITE HERE reports
Workers at hotels owned by RLJ Lodging Trust on both coasts walk off the job in effort to win wages and benefits that enable them to afford to raise families in... Read more.
Vertex Presents Updated Phase 1/2 Data From RUBY-3 Study That Continue to Demonstrate Best-in-Class Potential for Povetacicept in Adults with IgA Nephropathy and Primary Membranous Nephropathy at American Society of Nephrology Kidney Week
– 48-week data show a 64% decrease from baseline in proteinuria in IgA nephropathy, 82% decrease from baseline in proteinuria in primary membranous nephropathy,... Read more.
New Post Hoc Analysis from the HELIOS-B Phase 3 Study Shows Vutrisiran Improved Measures of Heart Structure and Function in Patients with ATTR-CM
− Analyses Presented at the American Heart Association Scientific Sessions 2025 Underscore Vutrisiran’s Differentiated Profile – − Cardiovascular Magnetic... Read more.
United States Otorhinolaryngology KOLs Fair-Market Value Compensation Rates Report 2025: An Independent Reference for Negotiations with Thought Leaders (KOLs) and Healthcare Providers (HCPs) – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “United States Fair-Market Value Compensation Rates for Otorhinolaryngology KOLs” report has been added to ResearchAndMarkets.com’s... Read more.
Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Phase 3 CORALreef Lipids Trial
Enlicitide, designed to deliver antibody-like efficacy, has the potential to be the first approved oral PCSK9 inhibitor to lower LDL-C with a safety profile comparable... Read more.